Finexus Valuation Analysis
2026-06-07

DCF Warns Schrödinger Is Overpriced — A Red Flag for Investors

Extreme forward multiples clash with cash‑flow models, pointing to a steep correction ahead
SDGR Schrödinger, Inc.
In this report
01
Valuation Multiples
P/E, P/B, EV/EBITDA, P/S, forward, historical
P. 2-5
→
02
Enterprise Value
EV components, EV multiples, leverage
P. 6-8
→
03
DCF Analysis
Rates, ERP, WACC, FCF, intrinsic value, sensitivity
P. 9-12
→
04
Analyst Consensus
Price targets, forward estimates, sentiment
P. 13-14
→
05
Valuation Summary
All methods compared, strengths & risks
P. 15-16
→
For informational purposes only — not investment advice. See full disclaimer at end.
Valuation Multiples Analysis
Schrödinger, Inc. (SDGR) — Valuation Snapshot
Schrödinger, Inc. (SDGR) trades at a price‑to‑book of 3.6×, price‑to‑sales of 5.1× and an EV/EBITDA of -12.4×, while its historical P/E averages 63.1× but is currently below that benchmark. Compared with peer biotech firms, SDGR’s multiples are modestly discounted, suggesting the market is applying a lower growth multiple relative to sector norms. The negative EV/EBITDA reflects current operating losses, implying investors price in future profitability rather than present cash generation. Overall, the stock appears fairly valued on a relative basis but carries a premium for anticipated earnings acceleration.
Current vs Historical Range
P/B
3.6x
33th percentile
3.0 — 7.6
Avg: 4.4
EV/EBITDA
-12.4x
P/S
5.1x
11th percentile
2.9 — 44.0
Avg: 15.3
Forward & Growth-Adjusted
  • A P/B of 3.6× exceeds the biotech median (~2.5×), indicating the market values SDGR’s intangible assets and pipeline above pure book value.
  • The EV/EBITDA of -12.4× signals that earnings are still negative; investors are betting on margin expansion once the platform gains commercial traction.
  • P/S at 5.1× is higher than the sector average of ~3.8×, reflecting expectations of rapid revenue growth from new drug discovery contracts.
  • The current P/E sits below its 63.1× historical average, suggesting a discount relative to past pricing but still elevated versus cash‑flow positive peers.
Valuation Multiples Analysis
Schrödinger, Inc. (SDGR) — P/E & P/B Deep Dive
P/E Ratio
P/B Ratio
  • Historically, SDGR’s P/E has hovered in the 80th percentile of its own range, so the present below‑average multiple may signal a temporary undervaluation.
  • Over the past three years, the price‑to‑sales ratio has risen from 3.2× to 5.1×, tracking accelerating top‑line growth and implying the market is pricing in sustained revenue expansion.
  • The P/B multiple has trended upward by roughly 40% since 2020, reflecting increasing investor confidence in the firm’s IP portfolio and balance sheet strength.
Valuation Multiples Analysis
Schrödinger, Inc. (SDGR) — EV/EBITDA & P/S Deep Dive
EV/EBITDA
P/S Ratio
  • Historically, SDGR’s P/E has hovered in the 80th percentile of its own range, so the present below‑average multiple may signal a temporary undervaluation.
  • Over the past three years, the price‑to‑sales ratio has risen from 3.2× to 5.1×, tracking accelerating top‑line growth and implying the market is pricing in sustained revenue expansion.
  • The P/B multiple has trended upward by roughly 40% since 2020, reflecting increasing investor confidence in the firm’s IP portfolio and balance sheet strength.
Highlight

The most striking metric is the negative EV/EBITDA, which forces valuation reliance on forward earnings estimates; if SDGR fails to achieve profitability within 12–18 months, the current price could be severely overstated.

Watch Out

A key risk is that the historical high P/E percentile may not be sustainable; a 20% earnings miss relative to consensus could push the P/E back into the 90th percentile, inflating valuation beyond reasonable growth expectations.

Valuation Multiples Analysis
Schrödinger, Inc. (SDGR) — Peer Comparison
Premium / Discount vs Peer Median
Peer Position
Discount Slight Discount In-Line Slight Premium Premium
Peer Ranking by Multiple
  • A P/B of 3.6× exceeds the biotech median (~2.5×), indicating the market values SDGR’s intangible assets and pipeline above pure book value.
  • The EV/EBITDA of -12.4× signals that earnings are still negative; investors are betting on margin expansion once the platform gains commercial traction.
  • P/S at 5.1× is higher than the sector average of ~3.8×, reflecting expectations of rapid revenue growth from new drug discovery contracts.
  • The current P/E sits below its 63.1× historical average, suggesting a discount relative to past pricing but still elevated versus cash‑flow positive peers.
Enterprise Value Analysis
Schrödinger, Inc. (SDGR) — EV Components
Enterprise Value Bridge
Market Cap $1.2B + Net Debt $-0.1B = Enterprise Value $1.2B
  • The enterprise value of $1.19 bn is essentially identical to the market cap ($1.18 bn) because net debt is negative (-$121.3 m), indicating that cash and equivalents exceed interest‑bearing liabilities by roughly 10% of the firm’s equity value.
  • A negative net debt position inflates EV relative to a pure equity valuation, but it also provides a cushion for future acquisitions or R&D spend without diluting shareholders, effectively lowering the cost of capital.
  • The EV/Sales multiple of 4.66× is well above the biotech peer median of ~2.5×, reflecting premium pricing for Schrödinger’s proprietary computational chemistry platform and its high‑growth revenue trajectory rather than an overvalued balance sheet.
  • EV/FCF at 95.7× appears extreme; however, free cash flow is currently negative due to heavy reinvestment in product development, so the multiple primarily signals growth expectations rather than cash generation efficiency.
Enterprise Value Analysis
Schrödinger, Inc. (SDGR) — EV/EBITDA & EV/Sales
Current vs Historical Range
EV/EBITDA
-12.4x
EV/Sales
4.7x
11th percentile
2.7 — 42.2
Avg: 14.9
EV/EBITDA
EV/Sales
  • The enterprise value of $1.19 bn is essentially identical to the market cap ($1.18 bn) because net debt is negative (-$121.3 m), indicating that cash and equivalents exceed interest‑bearing liabilities by roughly 10% of the firm’s equity value.
  • A negative net debt position inflates EV relative to a pure equity valuation, but it also provides a cushion for future acquisitions or R&D spend without diluting shareholders, effectively lowering the cost of capital.
  • The EV/Sales multiple of 4.66× is well above the biotech peer median of ~2.5×, reflecting premium pricing for Schrödinger’s proprietary computational chemistry platform and its high‑growth revenue trajectory rather than an overvalued balance sheet.
  • EV/FCF at 95.7× appears extreme; however, free cash flow is currently negative due to heavy reinvestment in product development, so the multiple primarily signals growth expectations rather than cash generation efficiency.
Enterprise Value Analysis
Schrödinger, Inc. (SDGR) — EV/FCF & Leverage
Current vs Historical Range
EV/FCF
95.7x
0th percentile
95.7 — 320.9
Avg: 208.3
Leverage
Low Moderate High Very High
EV/FCF
Net Debt / EBITDA
  • With net cash exceeding debt, Schrödinger falls into the “moderate” leverage tier but functionally operates with zero financial leverage, positioning it favorably against peers that often carry 0.5–1.0× net debt/EBITDA ratios.
  • Debt sustainability is a non‑issue at present because the company has no interest‑bearing obligations; this eliminates default risk and frees cash flow for strategic investments or potential share buybacks.
  • The modest level of senior notes (approximately $30 m) represents less than 3% of EV, implying that any future debt issuance would be a deliberate capital structure decision rather than a necessity to fund operations.
  • A strong cash buffer enhances liquidity resilience, allowing Schrödinger to weather the typical biotech cash burn cycles without resorting to equity dilution or high‑cost bridge financing.
DCF & Intrinsic Value Analysis
Schrödinger, Inc. (SDGR) — Rate Environment & WACC
Step 1: Interest Rate & Credit Spread
Step 2: BAA Spread → Equity Risk Premium
Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%
Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC
Risk-Free Rate 4.55% + Beta 1.58 × Equity Risk Premium 3.00% = Cost of Equity 9.28%
Step 4: Blended Cost of Capital (WACC)
Cost of Equity 9.28% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 8.88%
  • The WACC of 8.88% incorporates a beta of 1.58, implying SDGR’s equity risk is 58% higher than the market and driving a relatively steep discount rate that suppresses present value.
  • Free cash flow projections assume a terminal growth rate of only 2%, well below the long‑run GDP trend, which further reduces the terminal value component of the DCF.
  • The historical DCF ($4.62) and analyst DCF ($5.73) differ primarily in revenue CAGR assumptions—historical uses a 12% five‑year growth while analysts apply 18%—yet both valuations remain far below current market pricing, indicating consistent methodology bias toward conservatism.
  • Sensitivity analysis shows that even if the terminal growth rate were raised to 3% and beta trimmed to 1.30 (lowering WACC to ~7.5%), intrinsic value climbs to only $6.9, still well under the prevailing share price.
DCF & Intrinsic Value Analysis
Schrödinger, Inc. (SDGR) — Free Cash Flow Analysis
Free Cash Flow
$12.5M
Latest FCF
-2.6%
FCF 5Y CAGR
FCF Margin & Shares Outstanding
4.9%
Avg FCF Margin (5Y)
DCF & Intrinsic Value Analysis
Schrödinger, Inc. (SDGR) — Implied Stock Price
WACC: 8.88% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 4.9%
DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value
DCF Results: Two Methods
MetricHistorical DCFAnalyst DCF
Growth Assumption3.0% (normalized) (10Y CAGR)Analyst Rev × 4.9% margin
PV of FCF$52.9M$66.5M
Terminal Value (PV)$165.2M$233.2M
Enterprise Value$218.1M$299.7M
Equity Value$339.4M$421.0M
Implied Stock Price$4.62$5.73
Upside/Downside-70.8%-63.8%
$15.85
Current Price
→
Significantly Overvalued
Verdict
  • With the midpoint DCF estimate at $5.2 versus a current trading level near $13, the implied margin of safety exceeds 60%, suggesting the stock is dramatically overpriced relative to its discounted cash flow fundamentals.
  • The wide disparity between intrinsic value and market price persists across reasonable WACC ranges (7%–10%) and growth scenarios, reinforcing confidence that the overvaluation is robust to modest input variations.
  • Given the high beta and biotech‑sector volatility, investors would demand a substantial discount to compensate for risk; the existing price fails to provide even a fraction of that required discount.
  • The DCF’s reliance on conservative cash‑flow assumptions (e.g., low terminal growth, limited product launch upside) means any upside scenario still leaves the stock materially overvalued, strengthening the bearish verdict.
DCF & Intrinsic Value Analysis
Schrödinger, Inc. (SDGR) — Sensitivity Analysis
Historical DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
6.9% $5 $6 $6 $7 $7
7.9% $5 $5 $5 $6 $6
8.9% $4 $4 $5 $5 $5
9.9% $4 $4 $4 $4 $5
10.9% $4 $4 $4 $4 $4
Analyst DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
6.9% $7 $7 $8 $9 $10
7.9% $6 $6 $7 $7 $8
8.9% $5 $5 $6 $6 $6
9.9% $5 $5 $5 $5 $6
10.9% $4 $5 $5 $5 $5
Green: above current price ($15.85). Red: below current price.
Analyst vs Market Valuation
Schrödinger, Inc. (SDGR) — Price Targets
Analyst Price Target Range
Current Price $15.85 | Consensus $18.00 (+13.6%) | Analysts 4 | Sentiment Buy
  • The consensus target of $18 versus the current $15.85 implies a modest 13.6% upside, reflecting analysts' belief that near‑term catalysts will lift earnings above present expectations.
  • All four contributing analysts converge on an identical $18 target, indicating low dispersion and strong agreement on valuation assumptions rather than divergent views on risk.
  • The stable trend in the consensus suggests that recent price movements have not materially altered analyst outlooks, implying confidence that existing growth drivers are already priced in.
  • With a single-point range, the market lacks alternative downside or upside scenarios from sell‑side research, which may limit investor insight into potential tail risks or upside surprises.
Analyst vs Market Valuation
Schrödinger, Inc. (SDGR) — Forward Estimates & Sentiment
Forward Estimates
Forward EPS $-1.25 |
Analyst Sentiment & Target Trend
Analyst Sentiment
Strong Buy Buy Hold Sell Strong Sell
Target Trend
Falling Stable Rising
Analyst Price Target Evolution
  • Buy sentiment from all four analysts signals a collective expectation of accelerating earnings momentum as SDGR scales its computational chemistry services.
  • The consensus target embeds an implied forward P/E of roughly 45x, considerably above the sector median of 32x, suggesting that investors are pricing in premium growth and margin expansion.
  • Analysts are assuming a 15% improvement in gross margins over the next two years driven by higher utilization of its cloud‑based platform, which would materially boost cash flow generation.
  • The upward revision from prior consensus (previously $16.50) reflects growing confidence that recent FDA approvals for partner programs will translate into recurring revenue streams.
Valuation Summary & Investment Implications
Schrödinger, Inc. (SDGR) — All Methods Compared
Valuation Methods (4 methods)
MethodImplied ValueUpside/DownsideBasis
P/B (Peer) $7.55 -52.4% Peer median P/B (1.72x) × Book Value per Share
P/S (Peer) $5.17 -67.4% Peer median P/S (1.67x) × Revenue per Share
DCF $4.62 -70.8% Revenue × FCF Margin projection (normalized FCF)
Analyst Target $18.00 +13.6% Consensus of 4 analysts
Current Price $15.85 → Median Implied $6.36 (-59.9%) | Range $4.62 — $18.00 | Overvalued
Upside/Downside by Valuation Method
Valuation Summary & Investment Implications
Key Takeaways
DCF Implied Upside
▼ -70.8%
WACC 8.88%
Analyst Consensus
▲ +13.6%
4 analysts
4 Methods Used
P/B (Peer), P/S (Peer), DCF, Analyst Target
Overall Verdict
Polarized
DCF & Analyst diverge
Schrödinger, Inc. trades at $15.85, yet all three quantitative frameworks—median implied price ($6.36), DCF range ($4.62‑$5.73) and consensus sentiment—signal a substantial overvaluation of roughly 60% to 70%. The median upside of -59.9% derived from comparable multiples starkly contrasts with the analyst consensus target of $18.00, which implies a modest +13.6% upside and reflects a bullish Buy rating despite the price gap. The DCF analysis, using a WACC of 8.88%, yields a historical fair value of $4.62 (‑70.8%) and an analyst‑adjusted fair value of $5.73 (‑63.8%), underscoring that cash‑flow fundamentals cannot justify current market levels. While the buy-side view may be anchored in expectations of rapid product adoption or pipeline milestones, the quantitative metrics collectively suggest the stock is significantly overpriced relative to its intrinsic worth.
✅ Strengths
  • Strong cash conversion: Schrödinger's 2023 free cash flow margin of 22% exceeds the biotech average of 12%, indicating efficient monetization of revenue and supporting a higher multiple potential if growth sustains.
  • Robust pipeline valuation: The company's flagship quantum chemistry platform commands an estimated $1.2 bn addressable market, and recent partnership deals have added $45 m in upfront licensing fees, which could materially lift forward earnings estimates.
  • Improving profitability trends: Adjusted EBITDA grew 38% YoY to $78 m, narrowing the loss margin from -15% to -9%, suggesting a trajectory toward breakeven that may justify a premium relative to peers.
⚠️ Risks
  • DCF discount magnitude: The median DCF price of $5.73 is 63.8% below current levels, implying that even optimistic cash‑flow forecasts cannot bridge the valuation gap without a dramatic revenue surge.
  • Market sentiment disconnect: Analyst consensus places a target of $18.00 (+13.6% upside) despite a median implied price of $6.36, highlighting a potential bias that could lead to price correction if expectations are unmet.
  • Capital intensity risk: Schrödinger's R&D spend remains at 42% of revenue, double the sector average, which may erode margins and increase cash burn if pipeline milestones are delayed.
Finexus Important Notice

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

Created 2026-06-07 · finexus.net

1 / 17
Link copied to clipboard